Author:
Dubiella Christian,Pinch Benika J.,Zaidman Daniel,Manz Theresa D.,Poon Evon,He Shuning,Resnick Efrat,Langer Ellen M.,Daniel Colin J.,Seo Hyuk-Soo,Chen Ying,Ficarro Scott B.,Jamin Yann,Lian Xiaolan,Kibe Shin,Kozono Shingo,Koikawa Kazuhiro,Doctor Zainab M.,Nabet Behnam,Browne Christopher M.,Yang Annan,Stoler-Barak Liat,Shah Richa B.,Vangos Nick E.,Geffken Ezekiel A.,Oren Roni,Sidi Samuel,Shulman Ziv,Wang Chu,Marto Jarrod A.,Dhe-Paganon Sirano,Look Thomas,Zhou Xiao Zhen,Lu Kun Ping,Sears Rosalie C.,Chesler Louis,Gray Nathanael S.,London Nir
Abstract
AbstractThe peptidyl-prolyl cis-trans isomerase, Pin1, acts as a unified signaling hub that is exploited in cancer to activate oncogenes and inactivate tumor suppressors, in particular through up-regulation of c-Myc target genes. However, despite considerable efforts, Pin1 has remained an elusive drug target. Here, we screened an electrophilic fragment library to discover covalent inhibitors targeting Pin1’s active site nucleophile - Cys113, leading to the development of Sulfopin, a double-digit nanomolar Pin1 inhibitor. Sulfopin is highly selective for Pin1, as validated by two independent chemoproteomics methods, achieves potent cellular andin vivotarget engagement, and phenocopies genetic knockout of Pin1. Although Pin1 inhibition had a modest effect on viability in cancer cell cultures, Sulfopin induced downregulation of c-Myc target genes and reduced tumor initiation and tumor progression in murine and zebrafish models of MYCN-driven neuroblastoma. Our results suggest that Sulfopin is a suitable chemical probe for assessing Pin1-dependent pharmacology in cells andin vivo. Moreover, these studies indicate that Pin1 should be further investigated as a potential cancer target.
Publisher
Cold Spring Harbor Laboratory
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献